Aquestive Therapeutics’ (AQST) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQSTFree Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $9.00 target price on the stock.

Several other research analysts have also recently issued reports on AQST. Raymond James initiated coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an outperform rating and a $7.00 price objective on the stock. Piper Sandler initiated coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an overweight rating and a $10.00 price objective on the stock. JMP Securities increased their price objective on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an outperform rating in a research note on Friday, March 15th. Leerink Partnrs raised Aquestive Therapeutics to a strong-buy rating in a research note on Friday, May 10th. Finally, SVB Leerink initiated coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They issued an outperform rating and a $8.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Buy and an average price target of $8.00.

Read Our Latest Research Report on Aquestive Therapeutics

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $2.99 on Wednesday. The business’s 50 day moving average price is $3.60 and its 200-day moving average price is $3.13. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The company has a market cap of $272.21 million, a price-to-earnings ratio of -7.12 and a beta of 2.81.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $12.22 million. During the same quarter last year, the firm posted $0.11 EPS. Sell-side analysts predict that Aquestive Therapeutics will post -0.42 earnings per share for the current year.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 25,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the sale, the insider now owns 1,040,371 shares of the company’s stock, valued at approximately $5,399,525.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.85% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Aquestive Therapeutics in the 1st quarter worth $54,000. Lazard Asset Management LLC raised its stake in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. Jump Financial LLC purchased a new position in Aquestive Therapeutics in the 4th quarter worth $60,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Aquestive Therapeutics by 14.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after acquiring an additional 30,898 shares during the last quarter. Finally, PFG Investments LLC purchased a new position in Aquestive Therapeutics in the 1st quarter worth $204,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Featured Stories

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.